CLEVELAND — Facing annual spikes in pharmaceutical costs, major hospitals nationwide are curtailing use of expensive drugs and rejecting new additions to their formularies, sometimes triggering tense debates with clinicians who want to offer cutting-edge medications to their patients.

The conflict, involving a wide array of drugs, is bound to become more intense amid the specter of a GOP-led health care overhaul that could further undermine hospital finances. Already, hospitals are cutting down on use of certain pain medications and carefully scrutinizing requests to add expensive new drugs to treat conditions ranging from epilepsy to cancer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • We have a policy pricing disconnect between patented high priced marginal efficacy drugs and underpriced generic injectables no longer manufactured in the USA, in shortage and with rapidly escalating prices. Time for President Trump, negotiator in chief, to bring big PHARMA to the table along with GPOs that are anti-kickback antitrust immune and tell them that the party is over. Either manufacture generics in USA in abundant supply so that pricing power for innovation is preserved or face governmental negotiation of prices for innovative drugs.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy